One of this century’s biggest game-changers will likely be a novel drug class that’s showing unprecedented success, or the promise of it, in treating some of the world’s most prevalent conditions.
In the sixth white paper in our Ipsos Views Conversations with AI series, we explore the role of a Moderator Bot powered by generative AI within qualitative research.
The advent of groundbreaking therapies in the metabolic sector, including GLP-1, offers substantial opportunities for pharmaceutical companies, yet accurately estimating the size of these emerging markets, marked by significant unmet clinical needs, presents distinct challenges.
As economic stresses are preventing many from realising their long-term dreams, a sometimes- but-not-always-fatalistic “live for the moment” attitude is rising. Focus on helping people bridge the gap between their aspirations and their realities.
